NBIX is a biopharmaceutical company that discovers, develops, and markets drugs to treat neurological, neuroendocrine, and neuropsychiatric disorders. The company's first-quarter fiscal 2026 earnings report showed over $800 million in net product sales, led by INGREZZA's 44% year-over-year growth, net income of around $200 million, and a strong product pipeline (12 current programs with five more slated for launch this year).